A cross-country review of data collected on non-small cell lung cancer (NSCLC) patients in cancer registries, databases, retrospective and non-randomized prospective studies

References

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-50
   PubMed Web of Science ®Google Scholar
• Spiro SG, Tanner NT, Silvestri GA, et al. Lung cancer: progress in diagnosis, staging and therapy. Respirology 2010;15:44-50
   PubMed Web of Science ®Google Scholar
• Toh CK. The changing epidemiology of lung cancer. Methods Mol Biol 2009;472:397-411
   PubMedGoogle Scholar
• Youlden DR, Cramb SM, Baade PD. The International epidemiology of lung cancer: geographical distribution and secular trends. J Thorac Oncol 2008;3:819-31
   PubMed Web of Science ®Google Scholar
• Triano LR, Deshpande H, Gettinger SN. Management of patients with advanced non-small cell lung cancer: current and emerging options. Drugs 2010;70:167-79
   PubMed Web of Science ®Google Scholar
• National cancer control programmes. Geneva: WHO, 2012. http://www.who.int/cancer/nccp/en/. Accessed May 2012
   Google Scholar
• 58th World Health Assembly approved resolution on cancer prevention and control. Geneva: WHO, 2012. http://www.who.int/cancer/eb1143/en/index.html. Accessed May 2012
   Google Scholar
• European Partnership for Action Against Cancer. Cancer. EC. 2009. http://ec.europa.eu/health/major_chronic_diseases/diseases/cancer/index_en.htm#fragment1. Accessed November 2010
   Google Scholar
• Asahina H, Sekine I, Horinouchi H, et al. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer. Clin Lung Cancer 2012;13:39-43
   PubMed Web of Science ®Google Scholar
• Bischoff HG, van den Borne B, Pimentel FL, et al. Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin 2010;26:1461-70
   PubMed Web of Science ®Google Scholar
• Girard N, Jacoulet P, Gainet M, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol 2009;4:1544-9
   PubMed Web of Science ®Google Scholar
• Greer JA, Pirl WF, Park ER, et al. Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer. J Psychosom Res 2008;65:549-52
   PubMed Web of Science ®Google Scholar
• Isla D, Gonzalez-Rojas N, Nieves D, et al. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol 2011;13:460-71
   PubMed Web of Science ®Google Scholar
• Koeppler H, Heymanns J, Thomalla J, et al. Treatment of advanced non small cell lung cancer in routine care: a retrospective analysis of 212 consecutive patients treated in a community based oncology group practice. Clin Med Oncol 2009;3:63-70
   PubMedGoogle Scholar
• Moro-Sibilot D, Vergnenegre A, Smit EF, et al. Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Curr Med Res Opin 2010;26:2661-72
   PubMed Web of Science ®Google Scholar
• Murillo JR, Jr Koeller J. Chemotherapy given near the end of life by community oncologists for advanced non-small cell lung cancer. Oncologist 2006;11:1095-9
   PubMed Web of Science ®Google Scholar
• Naime FF, Younes RN, Kersten BG, et al. Metastatic non-small cell lung cancer in Brazil: treatment heterogeneity in routine clinical practice. Clinics (Sao Paulo) 2007;62:397-404
   PubMed Web of Science ®Google Scholar
• Pompen M, Gok M, Novak A, et al. Direct costs associated with the disease management of patients with unresectable advanced non-small-cell lung cancer in The Netherlands. Lung Cancer 2009;64:110-6
   PubMed Web of Science ®Google Scholar
• Ramsey SD, Howlader N, Etzioni RD, et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004;22:4971-8
   PubMed Web of Science ®Google Scholar
• Stokes ME, Muehlenbein CE, Marciniak MD, et al. Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009;15:669-82
   PubMed Web of Science ®Google Scholar
• Zietemann V, Duell T. Every-day clinical practice in patients with advanced non-small-cell lung cancer. Lung Cancer 2010;68:273-7
   PubMed Web of Science ®Google Scholar
• Zietemann V, Duell T. Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer. Lung Cancer 2011;73:70-7
   PubMed Web of Science ®Google Scholar
• Ardavanis A, Koumna S, Fragos I, et al. Erlotinib monotherapy in patients with advanced non-small cell lung cancer: an effective approach with low toxicity. Anticancer Res 2008;28:2409-15
   PubMed Web of Science ®Google Scholar
• Bando H, Miyata J, Sano T, et al. Retrospective analysis of administration of a combination of docetaxel and carboplatin for advanced non-small cell lung cancer. Anticancer Res 2001;21:2107-13
   PubMed Web of Science ®Google Scholar
• Bearz A, Garassino I, Cavina R, et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008;60:240-5
   PubMedGoogle Scholar
• Behera D, Aggarwal AN, Sharma SC, et al. Ifosfamide containing regimen for non-small cell lung cancer. Indian J Chest Dis Allied Sci 2004;46:9-15
   PubMedGoogle Scholar
• Brunetto AT, Carden CP, Myerson J, et al. Modest reductions in dose intensity and drug-induced neutropenia have no major impact on survival of patients with non-small cell lung cancer treated with platinum-doublet chemotherapy. J Thorac Oncol 2010;5:1397-403
   PubMed Web of Science ®Google Scholar
• Chiu CH, Tsai CM, Chen YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005;47:129-38
   PubMed Web of Science ®Google Scholar
• Chun SH, Lee JE, Park MH, et al. Gemcitabine Plus Platinum Combination Chemotherapy for elderly patients with advanced non-small cell lung cancer: a retrospective analysis. Cancer Res Treat 2011;43:217-24
   PubMed Web of Science ®Google Scholar
• Chung FT, Lee KY, Fang YF, et al. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer. Chemotherapy 2011;57:147-55
   PubMed Web of Science ®Google Scholar
• Dongiovanni D, Daniele L, Barone C, et al. Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)? Lung Cancer 2008;61:73-81
   PubMed Web of Science ®Google Scholar
• Genestreti G, Giovannini N, Frizziero M, et al. Carboplatin and gemcitabine in first-line treatment of elderly patients with advanced non-small cell lung cancer: data from a retrospective study. J Chemother 2011;23:232-7
   PubMed Web of Science ®Google Scholar
• Gielda BT, Marsh JC, Zusag TW, et al. Split-course chemoradiotherapy for locally advanced non-small cell lung cancer: a single-institution experience of 144 patients. J Thorac Oncol 2011;6:1079-86
   PubMed Web of Science ®Google Scholar
• Govindan R, Natale R, Wade J, et al. Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer 2006;53:331-7
   PubMed Web of Science ®Google Scholar
• Ho C, Murray N, Laskin J, et al. Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America. Lung Cancer 2005;49:225-31
   PubMed Web of Science ®Google Scholar
• Huang EH, Liao Z, Cox JD, et al. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 2007;68:779-85
   PubMed Web of Science ®Google Scholar
• Janne PA, Gurubhagavatula S, Yeap BY, et al. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer 2004;44:221-30
   PubMed Web of Science ®Google Scholar
• Ko YH, Lee MA, Hong YS, et al. Docetaxel monotherapy as second-line treatment for pretreated advanced non-small cell lung cancer patients. Korean J Intern Med 2007;22:178-85
   PubMedGoogle Scholar
• Kocak M, Mayadagli A, Ozkan A, et al. Outcome of metastatic non-small cell lung carcinoma patients receiving docetaxelcisplatin combination chemotherapy: single institution experience. J BUON 2007;12:471-6
   PubMed Web of Science ®Google Scholar
• Koizumi T, Agatsuma T, Ikegami K, et al. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib. Clin Lung Cancer 2012. Mar 6. Epub ahead of print
   Google Scholar
• Kommareddy A, Coplin MA, Gao F, et al. Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience. Lung Cancer 2004;45:221-5
   PubMed Web of Science ®Google Scholar
• Kuo CH, Lin SM, Lee KY, et al. Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance. Clin Lung Cancer 2010;11:51-6
   PubMed Web of Science ®Google Scholar
• Laohavinij S, Maneechavakajorn J. Prognostic factors for survival in advanced non-small cell lung cancer. J Med Assoc Thai 2004;87:1056-64
   PubMedGoogle Scholar
• Lee DH, Han JY, Kim HT, et al. Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients. Lung Cancer 2006;53:339-45
   PubMed Web of Science ®Google Scholar
• Lee HW, Choi JH, Lim HY, et al. The addition of induction chemotherapy with etoposide, ifosfamide, and cisplatin failed to improve therapeutic outcome of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer – single institution retrospective analysis. Neoplasma 2006;53:30-6
   PubMed Web of Science ®Google Scholar
• Liao ZX, Komaki RR, Thames HD, Jr et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010;76:775-81
   PubMed Web of Science ®Google Scholar
• Massarelli E, Andre F, Liu DD, et al. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 2003;39:55-61
   PubMed Web of Science ®Google Scholar
• Melosky B, Agulnik J, Assi H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 2008;15:279-85
   PubMed Web of Science ®Google Scholar
• Metro G, Chiari R, Mare M, et al. Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 2011;68:1405-12
   PubMed Web of Science ®Google Scholar
• Mohamed MK, Ramalingam S, Lin Y, et al. Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer. Ann Oncol 2005;16:780-5
   PubMed Web of Science ®Google Scholar
• Nadler E, Yu E, Ravelo A, et al. Bevacizumab treatment to progression after chemotherapy: outcomes from a U.S. community practice network. Oncologist 2011;16:486-96
   PubMed Web of Science ®Google Scholar
• Nadler E, Forsyth M, Satram-Hoang S, et al. Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. J Thorac Oncol 2012;7:212-8
   PubMed Web of Science ®Google Scholar
• Nakamura Y, Kunitoh H, Kubota K, et al. Retrospective analysis of safety and efficacy of low-dose docetaxel 60 mg/m2 in advanced non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Am J Clin Oncol 2003;26:459-64
   PubMed Web of Science ®Google Scholar
• Ng R, Loreto M, Lee R, et al. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 2008;61:262-5
   PubMed Web of Science ®Google Scholar
• Ono A, Naito T, Murakami H, et al. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. Int J Clin Oncol 2010;15:161-5
   PubMed Web of Science ®Google Scholar
• Oshita F, Miyagi Y, Honda T, et al. Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status. J Exp Ther Oncol 2010;8:313-9
   PubMedGoogle Scholar
• Parikh P, Chang AY, Nag S, et al. Clinical experience with gefitinib in Indian patients. J Thorac Oncol 2008;3:380-5
   PubMed Web of Science ®Google Scholar
• Park J, Park BB, Kim JY, et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 2004;10:4383-8
   PubMed Web of Science ®Google Scholar
• Pezzuolo D, Pennucci MC, Mambrini A, et al. Low dose fractionated cisplatin plus gemcitabine for elderly patients with advanced non small cell lung cancer: a retrospective analysis. J Chemother 2010;22:275-9
   PubMed Web of Science ®Google Scholar
• Platania M, Agustoni F, Formisano B, et al. Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer. Target Oncol 2011;6:181-6
   PubMed Web of Science ®Google Scholar
• Razis E, Skarlos D, Briasoulis E, et al. Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program. Anticancer Drugs 2005;16:191-8
   PubMed Web of Science ®Google Scholar
• Seto T, Yamanaka T, Nakano M, et al. Tegafur-uracil plus gemcitabine combination chemotherapy in patients with advanced non-small cell lung cancer previously treated with platinum. J Thorac Oncol 2008;3:637-42
   PubMed Web of Science ®Google Scholar
• Stepanski EJ, Houts AC, Schwartzberg LS, et al. Second- and third-line treatment of patients with non-small-cell lung cancer with erlotinib in the community setting: retrospective study of patient healthcare utilization and symptom burden. Clin Lung Cancer 2009;10:426-32
   PubMed Web of Science ®Google Scholar
• Tham CK, Choo SP, Lim WT, et al. Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis. J Thorac Oncol 2009;4:988-93
   PubMed Web of Science ®Google Scholar
• Unlu I, Diniz G, Komurcuoglu B, et al. Comparison of curative and palliative radiotherapy efficacy in unresectable advanced non-small cell lung cancer patients with or without metastasis. Saudi Med J 2006;27:849-53
   PubMed Web of Science ®Google Scholar
• Uruga H, Kishi K, Fujii T, et al. Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis. Intern Med 2010;49:103-7
   PubMed Web of Science ®Google Scholar
• van PR, Bosquee L, Meert AP, et al. Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study. Eur Respir J 2007;29:128-33
   PubMed Web of Science ®Google Scholar
• Wang J, Xia TY, Wang YJ, et al. Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2011;81:e59-e65
   PubMed Web of Science ®Google Scholar
• Wang L, Liao ML, Li LY, et al. Clinical benefit of gemcitabine plus cisplatin 3-week regimen for patients with advanced non-small cell lung cancer: a prospective observational study. Chin Med J (Engl) 2004;117:1607-10
   PubMed Web of Science ®Google Scholar
• Watanabe S, Tanaka J, Ota T, et al. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis. BMC Cancer 2011;11:1
   PubMed Web of Science ®Google Scholar
• Wataya H, Okamoto T, Maruyama R, et al. Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib. Lung Cancer 2009;64:341-5
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Shih JY, et al. Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer. Lung Cancer 2010;67:348-54
   PubMed Web of Science ®Google Scholar
• Zhu YJ, Xia Y, Ren GJ, et al. Efficacy and clinical/molecular predictors of erlotinib monotherapy for Chinese advanced non-small cell lung cancer. Chin Med J (Engl) 2010;123:3200-5
   PubMed Web of Science ®Google Scholar
• Altundag O, Stewart DJ, Fossella FV, et al. Many patients 80 years and older with advanced non-small cell lung cancer (NSCLC) can tolerate chemotherapy. J Thorac Oncol 2007;2:141-6
   PubMed Web of Science ®Google Scholar
• Molnar TF, Baliko Z, Sarosi V, et al. Survival after surgery following chemotherapy for non-small-cell lung cancer. Asian Cardiovasc Thorac Ann 2010;18:141-6
   PubMedGoogle Scholar
• Rasco DW, Yan J, Xie Y, et al. Looking beyond surveillance, epidemiology, and end results: patterns of chemotherapy administration for advanced non-small cell lung cancer in a contemporary, diverse population. J Thorac Oncol 2010;5:1529-35
   PubMed Web of Science ®Google Scholar
• Saito AM, Landrum MB, Neville BA, et al. The effect on survival of continuing chemotherapy to near death. BMC Palliat Care 2011;10:14
   PubMed Web of Science ®Google Scholar
• Gerber DE, Rasco DW, Le P, et al. Predictors and impact of second-line chemotherapy for advanced non-small cell lung cancer in the United States: real-world considerations for maintenance therapy. J Thorac Oncol 2011;6:365-71
   PubMed Web of Science ®Google Scholar
• Younes RN, Pereira JR, Fares AL, et al. Chemotherapy beyond first-line in stage IV metastatic non-small cell lung cancer. Rev Assoc Med Bras 2011;57:686-91
   PubMed Web of Science ®Google Scholar
• Bradbury PA, Tu D, Seymour L, et al. Economic analysis: randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 2010;102:298-306
   PubMed Web of Science ®Google Scholar
• Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004;90:397-402
   PubMed Web of Science ®Google Scholar
• Fox KM, Brooks JM, Kim J. Metastatic non-small cell lung cancer: costs associated with disease progression. Am J Manag Care 2008;14:565-71
   PubMed Web of Science ®Google Scholar
• Gridelli C, Ferrara C, Guerriero C, et al. Informal caregiving burden in advanced non-small cell lung cancer: the HABIT study. J Thorac Oncol 2007;2:475-80
   PubMed Web of Science ®Google Scholar
• Kang S, Koh ES, Vinod SK, et al. Cost analysis of lung cancer management in South Western Sydney. J Med Imaging Radiat Oncol 2012;56:235-41
   PubMed Web of Science ®Google Scholar
• Lang K, Marciniak MD, Faries D, et al. Costs of first-line doublet chemotherapy and lifetime medical care in advanced non-small-cell lung cancer in the United States. Value Health 2009;12:481-8
   PubMed Web of Science ®Google Scholar
• Maslove L, Gower N, Spiro S, et al. Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer. Thorax 2005;60:564-9
   PubMed Web of Science ®Google Scholar
• Navaratnam S, Kliewer EV, Butler J, et al. Population-based patterns and cost of management of metastatic non-small cell lung cancer after completion of chemotherapy until death. Lung Cancer 2010;70:110-5
   PubMed Web of Science ®Google Scholar
• Skowron A, Krzakowski M, Brandys J, et al. Cost analysis of chemotherapy in advanced non-small cell lung cancer. Nowotwory J Oncol 2001;51:565-9
   Google Scholar
• Doyle S, Lloyd A, Walker M. Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 2008;62:374-80
   PubMed Web of Science ®Google Scholar
• Lewis G, Peake M, Aultman R, et al. Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell lung cancer in the United Kingdom. J Int Med Res 2010;38:9-21
   PubMed Web of Science ®Google Scholar
• Nafees B, Stafford M, Gavriel S, et al. Health state utilities for non small cell lung cancer. Health Qual Life Outcomes 2008;6:84
   PubMed Web of Science ®Google Scholar
• Belani CP, Pereira JR, von PJ, et al. Effect of chemotherapy for advanced non-small cell lung cancer on patients' quality of life. A randomized controlled trial. Lung Cancer 2006;53:231-9
   PubMed Web of Science ®Google Scholar
• van den Hout WB, Kramer GW, Noordijk EM, et al. Cost-utility analysis of short- versus long-course palliative radiotherapy in patients with non-small-cell lung cancer. J Natl Cancer Inst 2006;98:1786-94
   PubMedGoogle Scholar
• Trippoli S, Vaiani M, Lucioni C, et al. Quality of life and utility in patients with non-small cell lung cancer. Quality-of-life Study Group of the Master 2 Project in Pharmacoeconomics. Pharmacoeconomics 2001;19:855-63
   PubMed Web of Science ®Google Scholar
• Schuette W, Tesch H, Buttner H, et al. Second-line treatment of stage III/IV non-small-cell lung cancer (NSCLC) with pemetrexed in routine clinical practice: evaluation of performance status and health-related quality of life. BMC Cancer 2012;12:14
   PubMed Web of Science ®Google Scholar
• Cancers. Institut de veille sanitaire. 2012. http://www.invs.sante.fr/surveillance/cancers/. Accessed May 2012
   Google Scholar
• BancaDati. Associazione Italiano Registri Tumori (AIRTUM) 2012. http://www.registri-tumori.it/cms/bancadati#. Accessed May 2012
   Google Scholar
• Izmir Cancer registry. KIDEM. 2012. http://www.ism.gov.tr/kidem/index.html. Accessed May 2012
   Google Scholar
• Molinier L, Combescure C, Chouaid C, et al. Cost of lung cancer: a methodological review. Pharmacoeconomics 2006;24:651-9
   PubMed Web of Science ®Google Scholar
• Cancer Dataset. NHS. 2012. http://www.ic.nhs.uk/services/datasets/dataset-list/cancer. Accessed May 2012
   Google Scholar
• Parkin DM. The evolution of the population-based cancer registry. Nat Rev Cancer 2006;6:603-12
   PubMed Web of Science ®Google Scholar